<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074369</url>
  </required_header>
  <id_info>
    <org_study_id>20190601</org_study_id>
    <nct_id>NCT04074369</nct_id>
  </id_info>
  <brief_title>Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects</brief_title>
  <official_title>Evaluation of CRISPR-based Test for the Rapid Identification of Mycobacterium Tuberculosis Complex in Pulmonary Tuberculosis Suspects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wenzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a
      prospective study of pulmonary TB suspects who are undergoing sputum or bronchoalveolar
      lavage fluid (BALF) evaluation for pulmonary TB. The sensitivity and specificity of the
      CRISPR-based assay will be compared to clinical diagnosis, conventional culture methods and
      Xpert MTB/RIF assay on same batch specimens.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay positive and/or MGIT culture positive for M.tuberculosis.</measure>
    <time_frame>week 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay negative and/or MGIT culture negative for M.tuberculosis.</measure>
    <time_frame>week 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of clinically diagnosed non-TB participants with CRISPR-based test MTB positive in sputum/BALF.</measure>
    <time_frame>week 0</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Pulmonary Tuberculosis Suspects</arm_group_label>
    <description>Individuals with suspected TB infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CRISPR-based Test</intervention_name>
    <description>CRISPR-based Test performed on sputum or BALF in TB suspects.</description>
    <arm_group_label>Pulmonary Tuberculosis Suspects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Suspected pulmonary TB patients in Huashan Hospital, Wenzhou Central Hospital and Hangzhou
        Red Cross Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected pulmonary TB.

          -  Ability and willingness of candidate or legal guardian/representative to provide
             informed consent.

          -  Men and women age equal to or greater than 18 years.

        Exclusion Criteria:

          -  Either receipt of â‰¥48 cumulative hours OR three or more doses of anti-TB treatment
             within 180 days prior to completion of second sputum collection for Xpert testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenhong Zhang</last_name>
    <phone>(+86) 21 5288 7970</phone>
    <email>zhangwenhong@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingwen Ai</last_name>
    <phone>(+86) 21 5288 7970</phone>
    <email>jingwenai1990@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing-wen Ai</last_name>
      <phone>(+86) 21 5288 7970</phone>
      <email>jingwenai1990@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xian Zhou</last_name>
      <phone>(+86) 21 5288 7970</phone>
      <phone_ext>Zhou</phone_ext>
      <email>zhouxianhz@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Wen-hong Zhang</investigator_full_name>
    <investigator_title>Director of Division of Infectious Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

